Cag3 Is a Novel Essential Component of the Helicobacter pylori Cag Type IV Secretion System Outer Membrane Subcomplex

Delia M. Pinto-Santini; Nina R. Salama

首页> 外文期刊>Journal of bacteriology >Cag3 Is a Novel Essential Component of the Helicobacter pylori Cag Type IV Secretion System Outer Membrane Subcomplex

【24h】

Cag3 Is a Novel Essential Component of the Helicobacter pylori Cag Type IV Secretion System Outer Membrane Subcomplex

机译：Cag3是幽门螺杆菌Cag IV型分泌系统外膜亚复合物的新型必需成分。

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Helicobacter pylori strains harboring the cag pathogenicity island (PAI) have been associated with more severe gastric disease in infected humans. The cag PAI encodes a type IV secretion (T4S) system required for CagA translocation into host cells as well as induction of proinflammatory cytokines, such as interleukin-8 (IL-8). cag PAI genes sharing sequence similarity with T4S components from other bacteria are essential for Cag T4S function. Other cag PAI-encoded genes are also essential for Cag T4S, but lack of sequence-based or structural similarity with genes in existing databases has precluded a functional assignment for the encoded proteins. We have studied the role of one such protein, Cag3 (HP0522), in Cag T4S and determined Cag3 subcellular localization and protein interactions. Cag3 is membrane associated and copurifies with predicted inner and outer membrane Cag T4S components that are essential for Cag T4S as well as putative accessory factors. Coimmunoprecipitation and cross-linking experiments revealed specific interactions with HpVirB7 and CagM, suggesting Cag3 is a new component of the Cag T4S outer membrane subcomplex. Finally, lack of Cag3 lowers HpVirB7 steady-state levels, further indicating Cag3 makes a subcomplex with this protein.

机译：带有 cag 致病性岛（PAI）的幽门螺杆菌菌株与感染人类的更严重的胃病有关。 cag PAI编码CagA转运到宿主细胞以及诱导促炎细胞因子（如白介素8（IL-8））所需的IV型分泌（T4S）系统。 cag PAI基因与其他细菌的T4S组分具有序列相似性，对Cag T4S的功能至关重要。其他 cag PAI编码的基因对于Cag T4S也是必不可少的，但是与现有数据库中的基因缺乏基于序列或结构的相似性，因此无法对编码的蛋白质进行功能分配。我们已经研究了一种这样的蛋白Cag3（HP0522）在Cag T4S中的作用，并确定了Cag3亚细胞定位和蛋白相互作用。 Cag3与膜相关，并与预测的内膜和外膜Cag T4S组分共纯化，这些组分对于Cag T4S以及假定的辅助因子至关重要。免疫共沉淀和交联实验揭示了与HpVirB7和CagM的特异性相互作用，表明Cag3是Cag T4S外膜亚复合物的新成分。最后，缺乏Cag3会降低HpVirB7稳态水平，进一步表明Cag3与该蛋白形成了亚复合物。 展开▼

著录项

来源
《Journal of bacteriology》 |2009年第23期|共10页

作者
Delia M. Pinto-Santini; Nina R. Salama;
展开▼

作者单位

展开▼

收录信息

原文格式 PDF

正文语种

中图分类微生物学;

关键词

相似文献

外文文献

中文文献

专利

1. Cag-delta (Cag3) protein from the Helicobacter pylori 26695 cag type IV secretion system forms ring-like supramolecular assemblies [J] . Smart Jonathan, Fouillen Aurelien, Casu Bastien, FEMS Microbiology Letters . 2017,第1期

机译：来自幽门螺杆菌26695 CAG IV分泌系统的CAG-DELTA（CAG3）蛋白质形成环状超分子组件

2. Biochemical characterization of the Helicobacter pylori Cag-type IV secretion system unique component CagU [J] . Kumari Rajesh, Shariq Mohd, Kumar Navin, FEBS letters. . 2017,第3期

机译：幽门螺杆菌CAG型分泌系统独特组分CAGU的生化特征

3. Temporal Control of the Helicobacter pylori Cag Type IV Secretion System in a Mongolian Gerbil Model of Gastric Carcinogenesis [J] . Aung Soe Lin, Mark S. McClain, Amber C. Beckett, MBio . 2020,第3期

机译：<命名含量含量型=“属型”>幽门螺杆菌幽门螺杆菌胃癌胃癌模型中的幽门螺杆菌幽门螺杆菌和术语分泌系统

4. Identification of Helicobacter pylori proteins involved in the cag Type-IV secretion system apparatus via discovery and targeted mass spectrometry approaches [C] . Carrie L. Shaffer, W. Hayes McDonald, Salisha Hill, American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics . 2010

机译：通过发现和靶向质谱方法鉴定CAG型-IV分泌系统装置中涉及的幽门螺杆菌蛋白

5. Characterization of the cag type IV secretion system and unique filaments of Helicobacter pylori [D] . Couturier, Marc Roger 2008

机译：IV型cag分泌系统的特征和幽门螺杆菌的独特细丝

6. Cag3 Is a Novel Essential Component of the Helicobacter pylori Cag Type IV Secretion System Outer Membrane Subcomplex [O] . Delia M. Pinto-Santini, Nina R. Salama 2009

机译：Cag3是幽门螺杆菌Cag IV型分泌系统外膜亚复合物的新型必需成分。

7. Cag3 Is a Novel Essential Component of the Helicobacter pylori Cag Type IV Secretion System Outer Membrane Subcomplex ▿ † [O] . Pinto-Santini, Delia M., Salama, Nina R. 2009

机译：Cag3是幽门螺杆菌Cag IV型分泌系统外膜亚复合物的新型必需成分▿†

1. 幽门螺杆菌Ⅳ型分泌系统Cag3基因的克隆表达及其质谱鉴定 [J] . 刘俊 ,陈德玉 ,赵建忠 . 江苏医药 . 2013,第003期

2. 幽门螺杆菌cag PAI编码的Ⅳ型分泌系统 [J] . 崔蕾蕾 ,邵世和 . 微生物学报 . 2007,第004期

3. 细菌膜泡(ECV)、外膜蛋白复合物(OMPC)的氨基酸组成分析 [J] . 倪龙兴 ,史俊南 ,陈镔复 . 牙体牙髓牙周病学杂志 . 1994,第001期

4. 幽门螺杆菌感染患者血清可溶性幽门螺杆菌抗原及其 IgG,IgA型免疫复合物测定 [J] . 朱永良 ,林洁 ,李达 . 中华医学杂志 . 2002,第003期

5. 幽门螺杆菌Ⅳ型分泌系统 cagQ 基因缺失株的构建与鉴定 [J] . 姚逸正 ,王华 ,倪颖 . 江苏大学学报（医学版） . 2014,第006期

6. 幽门螺杆菌尿素酶B亚单位W/O/W型复乳的制备及免疫原性研究 [C] . 高志刚 ,邹全明 ,郭刚 . 中国药学会药剂专业委员会学术年会 . 2002

7. 幽门螺杆菌外膜蛋白双价亚单位融合疫苗的实验研究 [A] . 张卫军 . 2006

1. 新型环氧树脂及其制造方法、以该环氧树脂为必需成分的环氧树脂组合物及以该环氧树脂为必需成分的固化物 [P] . 中国专利： CN102037048B . 2012.10.10

2. 新型环氧树脂及其制造方法、以该环氧树脂为必需成分的环氧树脂组合物及以该环氧树脂为必需成分的固化物 [P] . 中国专利： CN102037048A . 2011-04-27

3. Compound, process for the preparation of it, pharmaceutical formulation, use of the compound, processes to inhibit gastric acid secretion, for the treatment of inflammatory gastrointestinal diseases, and for the treatment or prophylaxis of conditions involving helicobacter pylori infection of the mucosa human gastric, and, pharmaceutical formulations for use in inhibiting gastric acid secretion, for use in the treatment of inflammatory gastrointestinal diseases, and for use in the treatment or prophylaxis of conditions involving helicobacter pylori infection of the human gastric mucosa [P] . 外国专利： BR9913103A . 2001-05-08

机译：该化合物，其制备方法，药物制剂，该化合物的使用，抑制胃酸分泌的方法，用于治疗炎性胃肠疾病以及用于治疗或预防人胃黏膜幽门螺杆菌感染的疾病的方法，以及用于抑制胃酸分泌，用于治疗炎性胃肠疾病以及用于治疗或预防涉及人胃粘膜的幽门螺杆菌感染的疾病的药物制剂

4. composition, pharmaceutical composition, effervescent dosage form, multiple unit oral oral pharmaceutical composition, extended release pharmaceutical dosage form, enteric coated pharmaceutical dosage form, stable pharmaceutical dosage form for oral administration to mammalian subjects, method for treating diseases acid-related diseases by inhibiting gastric acid secretion, method for treating a bacterial infection caused or caused by helicobacter pylori, process for preparing a compound of formula 3, process for preparing a compound of formula 5, use of a compound of formula 1 for the preparation of a medicament for treating gastric acid-related diseases by inhibiting gastric acid secretion, use of a compound of formula 1 for the preparation of a medicament for treating a bacterial infection caused or caused by helicobacter pyl or use of a compound of formula 1 for the preparation of a medicament for treating gastric acid-related diseases by inhibiting gastric acid secretion [P] . 外国专利： BRPI0617987A2 . 2011-08-16

机译：组合物，药物组合物，泡腾剂型，多单位口服口服药物组合物，缓释药物剂型，肠溶衣药物剂型，向哺乳动物受试者口服给药的稳定药物剂型，通过抑制胃酸治疗疾病的方法酸分泌，治疗由幽门螺杆菌引起或引起的细菌感染的方法，制备式3化合物的方法，制备式5化合物的方法，式1化合物在制备用于治疗胃的药物中的用途通过抑制胃酸分泌来治疗与酸有关的疾病，将式1的化合物用于制备用于治疗由幽门螺杆菌引起或引起的细菌感染的药物，或将式1的化合物用于制备用于治疗的药物通过抑制胃酸分泌来治疗胃酸相关疾病

5. POLYPEPTIDE AND POLYPEPTIDE COMPOSITION FOR INHIBITING HELICOBACTER PYLORI FROM FORMING BIOLOGICAL MEMBRANE AND ELIMINATING BIOLOGICAL MEMBRANE FORMED BY HELICOBACTER PYLORI [P] . 外国专利： WO2021068478A1 . 2021-04-15

机译：用于抑制幽门螺杆菌的多肽和多肽组合物从形成生物膜和消除由幽门螺杆菌形成的生物膜

相关主题

Cag3 Is a Novel Essential Component of the Helicobacter pylori Cag Type IV Secretion System Outer Membrane Subcomplex

摘要

著录项

相似文献

相关主题

期刊订阅